Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Thomas Martin (ucsf)
Headshot of Thomas Martin
Thomas Martin

Description

Summary

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

Official Title

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Keywords

Multiple Myeloma, Plasma Cell Neoplasms, Lenalidomide, Pomalidomide, Daratumumab, Talquetamab, Carfilzomib, Daratumumab SC, Talquetamab + Carfilzomib, Talquetamab + Daratumumab + Carfilzomib, Talquetamab + Lenalidomide, Talquetamab + Daratumumab + Lenalidomide, Talquetamab + Pomalidomide

Eligibility

Locations

  • University of California San Francisco
    San Francisco California 94143 United States
  • Colorado Blood Cancer Institute
    Denver Colorado 80218 United States

Lead Scientist at University of California Health

  • Thomas Martin (ucsf)
    A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center. Martin is clinical research director of hematologic malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT05050097
Phase
Phase 1 Multiple Myeloma Research Study
Study Type
Interventional
Participants
About 166 people participating
Last Updated